Хвороби цивілізації: печінка і поліморбідний метаболічний континуум
DOI:
https://doi.org/10.30978/UTJ2018-2-91Ключові слова:
метаболічний синдром, дисліпідемія, жирова хвороба печінки, жовчні кислотиАнотація
У статті розглядається роль печінки в обміні ліпопротеїдів та можливості корекції його порушень в межах метаболічного синдрому як найбільш типового вияву поліморбідної патології сучасної цивілізації.Посилання
Агаджанян НА, Чижов АЯ, Ким ТА Болезни цивилизации. Экология человека. 2003.— № 4.— С. 811.
Верткин АЛ, Зайратьянц ОВ, Вовк ЕИ Окончательный диагноз.— М.: ГэотарМедиа, 2008.— 576 с.
Журавлева ЛВ, Кривоносова ЕМ Применение урсодезоксихолевой кислоты в комплексном лечении метаболического синдрома. Лікарські засоби. 2014.— № 4 (78).— С. 90-94.
Медведева В. Н, Курицина С. И, Медведев В. Н. Атеросклероз брюшной аорты и сонных артерий и его корреляция с содержанием липидов в сыворотке крови при желчнокаменной болезни. Кардиология. 2003.— № 16 (6).— C. 41-55.
Перова НВ Новые Европейские рекомендации по профилактике сердечнососудистых заболеваний, обусловленных атеросклерозом. Кардиология. 2004.— № 1.— С. 76-82.
Сычев ДА и соавт. Клиническая фармакогенетика.— М.: Гэотар, 2007.— 248с.
Танченко ОА, Нарышкина СВ, Сивяков ОН Урсодезоксихолевая кислота в комплексном лечении больных с метаболическим синдромом. Рос. журн. гастроэнтерол., гепатол., колопроктол. 2012.— Т. 22.— № 1.— С. 82-86.
Шилов АМ, Лоранская ИД, Михайлова АХ, Тарасенко ОФ Влияние патологии желчевыводящих путей на риск развития ишемической болезни сердца. РМЖ. 2008.— № 16 (25).— C. 1695-1698.
Angelico F, Burattin M, Alessandri C. et al. Drugs improving insulin resistance for nonalcoholic fatty liver disease and/or nonalcoholic steatohepatitis. Cochrane Database of Systematic Reviews. 2007.— Is. 1. Art. N CD005166.
Banu D. Ozel Coskun, Sebnem Gursoy, Mehmet Yucesoy, Gülden Başkol. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur J Gastroenterol Hepatol. 2015;27(2):142-149.
Betlejewski S. Social diseases, civilization diseases or lifestyle diseases?. Wiad Lek. 2007;60 (910):489-492.
Braun S, BittonWorms K, LeRoith D. The Link between the Metabolic Syndrome and Cancer. Int J Biol.Sci. 2011;7(7):10031015.
Canner PL, Furberg CD, McGovern ME. Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary DrugProject). Am J Cardiol. 2006;97:477-479.
CarreraBastos P, Fontes, O’Keefe J, Lindeberg S, Cordain L. The western diet and lifestyle and diseases of civilization. Res Reports Clin Cardiol. 2011;2:15-35.
Clark JM. The epidemiology of nonalcoholic fatty liver disease in adults. J Clin Gastroenterol. 2006;40(1):5-10.
Claudel T, Staels B, Kuipers F. The Farnesoid X. Receptor. A Molecular Link Between Bile Acid and Lipid and Glucose Metabolism. Arterioscler Thromb Vasc Biol. 2005;25:2020-2030.
Coskun O, Yucesoy M, Gursoy S, et al. Effects of ursodeoxycholic acid therapy on carotid intima media thickness, apolipoprotein A1, apolipoprotein B, and apolipoprotein B/A1 ratio in nonalcoholic steatohepatitis. Eur. J. Gastroenterol. Hepatol. 2015;27(2):142-149.
Davis HRJr, Compton DS, Hoos L, Tetzloff G. Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice. Arterioscler Thromb Vasc Biol. 2001;21:2032-2038.
Evozskaya Toth PP, Davidson MH. Cholesterol absorption blockade with ezetimibe. Curr Drug Targets. Cardiovasc Haematol Disord. 2005;5:455-462.
Farrell GC, Larter CZ. Nonalcoholic fatty liver disease: from steatosis to cirrhosis. Hepatol. 2006;43(2Suppl.1) S99-S112.
Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study: primaryprevention trial with gemfibrozil in middleaged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med. 1987;317:1237-1245.
FriisLiby I, Aldenborg F, Jerlstad P, et al. High prevalence of metabolic complications in patients with nonalcoholic fatty liver disease. Scand J Gastroenterol. 2004;39(9):864-869.
Ganji SH, Tavintharan S, Zhu D, Et al. Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells. J Lipid Res. 2004;45:1835-1845.
Gilat T, LeikinFrenkel A, Goldiner I, et al. Prevention of DietInduced Fatty Liver in Experimental аnimals By the Oral Administration of a Fatty Acid Bile Acid Conjugate (FABAC). Hepatol. 2003;38(2):436-442.
Houten SM, Watanabe M, Auwerx J. New EMBO Member’s Review. Endocrine functions of bile acids. EMBO J 2006;25:14191425.
Insull WJr. Clinical utility of bile acid sequestrants in the treatment of dyslipidemia: a scientific review. South Med J. 2006;99:257.
Lieber CS, Weiss DG, Groszmann R. et al. Veterans Affairs Cooperative Study 391 Group. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. Alcohol Clin Exp Res. 2003;27(11):176-572.
Lili Ding, Li Yanga Zhengtao Wang and Wendong Huang. Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin. B. 2015;5(2):135-144.
Mancia G, De Backer G, Dominiczak A, et al. 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2007;25(6):1105-1187.
Manninen V, Tenkanen L, Koskinen Pб Et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation. 1992;85:3745.
Marschall HU, Einarsson C. Gallstone disease. J Int Med. 2007;261:529-542.
McCormack PL, Keating GM Prolongedrelease nicotinic acid: a review of its use in the treatment of dyslipidaemia. Drugs. 2005;65:2719-2740.
National Cholesterol Education Program. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): final report. NIH Publication. 2002;2:4-9.
NeuschwanderTetri BA, Caldwell SH Nonalcoholic steatohepatitis: Summary of an AASLD Single Topic Conference. Hepatol. 2003;37(5):1202-1219.
Ong JP, Elariny H, Collantes R, et al. Predictors of nonalcoholic steatohepatitis and advanced fibrosis in morbidly obese patients. Obes Surg. 2005;15(3):310-315.
Ozturk K, Uygun Ah., Demirci H, Bagci S. Effect of ursodeoxycholic acid on atherosclerosis. Eur J Gastroenterol Hepatol. 2015;27(7):8-65.
Paoletti R, Bolego Ch, Poli A, Cignarella A. Metabolic Syndrome, Inflammation and Atherosclerosis. Vasc Health Risk Manag. 2006;2(2):145-152.
Pothiwala P, Sushil K Jain, Yaturu S. Metabolic syndrome and cancer. Metab Syndr Relat Disord. 2009;7(4):279-287.
Rubins HB, Robins SJ, Collins D, et al. Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs highdensity lipoprotein intervention trial (VAHIT). Arch Int Med. 2002;162:2597-2604.
Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of highdensity lipoprotein cholesterol. Veterans Affairs HighDensity Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341:410-418.
Sudhop TI, von Bergmann K. Inhibition of intestinal cholesterol absorption by ezetimibe in humans. Circulation. 2002;106:19431948.
Tenenbaum A, Fisman EZ, Motro M, Adler Y. Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins. Cardiovasc Diabetol. 2006;5:20.
The Coronary Drug Project Research Group: The Coronary DrugProject: Design, Methods, and Baseline Results. Circulation. 1973;47:150.
The ILIB Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease. Second Edition, New York, 2000.
Trijs C, Knupschild P, Brombaher P. Serum lipida and gallstones: a casecontrol study. Gastroenterol. 1990;99(3):843-849.
Troisi G, Crisciotti F, Gianturco V. The treatment with ursodeoxycholic acid in elderly patients affected by NAFLD and metabolic syndrome: a casecontrol study. Clin Ter. 2013;164(3):203-207.
Vague J. Sexual Differentiation, a Factor Affecting the Forms of Obesity. La Presse Médicale. 1947;30:339-340.
World health statistics 2016: monitoring health for the SDGs, sustainable development goals. WHO Library CataloguinginPublication Data, 2016:121.
Younossi ZM, Gramlich T, Matteoni CA, et al. Nonalcoholic fatty liver disease in patients with type 2 diabetes. Clin Gastroenterol Hepatol. 2004;2(3):262-265.
Yusuf S. Global Burden of Cardiovascular Diseases. Circulation. 2001;104:2746-2753.
